GO
| HSI1 | 25,752.40 | 0.00 | -- |
| HSCEI1 | 8,611.83 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP: Innovative Drug Naldemedine Approved for Marketing in Greater Bay Area
2026-04-09 17:35:58 SBP GROUP (01177.HK) announced that Naldemedine, an innovative drug exclusively licensed by its subsidiary, Chia Tai Tianqing Pharmaceutical, was approved by the Guangdong Medical Products Administration for an early launch in the Guangdong-Hong Kong-Macao Greater Bay Area for the treatment of opioid-induced constipation (OIC). ~ AAStocks Financial News Web Site: www.aastocks.com | |